BlueWeave Consulting

Increasing reimbursements for (STDs) testing across the countries, high prevalence and rise in incidences of across the world, and implementation of national screening programs are projected to propel the expansion of Global Sexually Transmitted Diseases (STDs) Testing Market during the period between 2023 and 2029.

🌐 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐭𝐡𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/dfJEPsVX

▶ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
✔ Abbott
✔ bioMérieux, Inc.
✔ BD Company
✔ Danaher Corporation
✔ Bio-Rad Laboratories
✔ Hologic, Inc.
✔ DiaSorin Molecular LLC
✔ Roche LEON HOLDINGS
✔ OraSure Technologies, Inc.
✔ Thermo Fisher Scientific
✔ AccuBioTech Co., Ltd., ✔ AdvaCare Pharma USA, ✔ Biogenix, ✔ CTK Biotech, Inc., ✔ Wohlfahrtsstiftung der F. Hoffmann-La Roche AG., ✔ Gilead Sciences, ✔ GSK, ✔ Merck.

📣 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐁𝐲 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: Global sexually transmitted disease testing market is divided into Chlamydia, Syphilis, Gonorrhoea, Hyper Simplex Virus, Human Immunodeficiency Virus, and Chancroid segments. The Chlamydia segment accounted for the highest in 2022. However, the infection segment is expected to skyrocket during the forecast period. The Centers for Disease Control and Prevention ( ) received 616,392 complaints of gonorrhea in 2019, making it the second most common reportable disease in the US.

Spurring for discovering efficient therapeutics for various types of is expected to expand the Global Market at a robust growth rate during the period.

Please visit the report: https://lnkd.in/duK8Bqet

Key Players: AstraZeneca
Vibalogics
Danaher Corporation (Cytiva)
Sanofi SA
Lonza
Thermo Fisher Scientific Inc.
Cognate BioServices, a Charles River Company Inc. (Cobra Biologics), FinVector Oy, FUJIFILM Holdings America Corporation, Corporation (Fujifilm Diosynth Biotechnologies), and . Hoffmann-La Roche Ltd (Spark Therapeutics), Kaneka North America.